FindTrial
Sign In

PET scan for measuring response in lymphoma of brain

A prospective study to evaluate the role of PET-CT in response evaluation of patients of primary CNS lymphoma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033776
Enrollment
50
Registered
2021-05-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C859- Non-Hodgkin lymphoma, unspecified

Interventions

Intervention1: PET-CT scan: PET-CT scan for response assessment will be done and compared with MRI brain at time point 2,4 and 6 months whenever a MRI brain is planned. Control Intervention1: MRI brai

Sponsors

Tata Memorial Centre Mumbai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosed cases of PCNSL 2. Receiving high dose methotrexate based induction therapy 3. Patient available for response assessment MRI & PET-CT Brain post induction chemotherapy 4. Patient able to understand & sign the consent.

Exclusion criteria

Exclusion criteria: 1.Patients who cannot complete the high dose methotrexate based induction chemotherapy due to toxicity or other reasons except progression . 2.Patient with any contrast allergies or hypersensitivities.

Design outcomes

Primary

MeasureTime frame
Sensitivity and specificity of PET-CT as compared to MRI (gold standard for response assessment)Timepoint: 2,4 and 6 months—

Secondary

MeasureTime frame
Prognostic value of MTV and TLGTimepoint: At start that time point "0";Prognostic value of PET responseTimepoint: 2, 4 and 6 months;Utility of PET-MRI fusionTimepoint: 2,4 and 6 months—

Countries

India

Contacts

Public ContactBhausaheb Bagal

Tata Memorial Centre, Mumbai.

bagalbp@gmail.com02224177210

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026